Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:05:54 ON 13 DEC 2009

=> file registry
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.22 | 0.22

FILE 'REGISTRY' ENTERED AT 16:06:21 ON 13 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 DEC 2009 HIGHEST RN 1197154-31-6
DICTIONARY FILE UPDATES: 11 DEC 2009 HIGHEST RN 1197154-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-591653genA.str



chain nodes :
11 12 19 20 21 22 23 24 25 26 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18
chain bonds :
2-28 4-27 8-11 11-12 12-13 12-29 16-19 19-20 19-26 20-21 21-22 21-25
22-23 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18
exact/norm bonds :
2-28 4-27 11-12 12-13 19-20 19-26 20-21

exact bonds :
8-11 12-29 16-19 21-22 21-25 22-23 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 16:20:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1651 TO ITERATE

100.0% PROCESSED   1651 ITERATIONS   267 ANSWERS
SEARCH TIME: 00.00.01

L2   267 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   196.92   197.14

FILE 'CAPLUS' ENTERED AT 16:20:34 ON 13 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Dec 2009 VOL 151 ISS 25
FILE LAST UPDATED: 11 Dec 2009 (20091211/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)

reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l2
L3       17643 L2

=> s l3 and "hyaluronic acid"
          19680 "HYALURONIC"
              1 "HYALURONICS"
          19680 "HYALURONIC"
                  ("HYALURONIC" OR "HYALURONICS")
        4960386 "ACID"
        1728183 "ACIDS"
        5498049 "ACID"
                  ("ACID" OR "ACIDS")
          19529 "HYALURONIC ACID"
                  ("HYALURONIC"(W)"ACID")
L4          265 L3 AND "HYALURONIC ACID"

=> s l4 and conjugate
          80574 CONJUGATE
          74545 CONJUGATES
         127449 CONJUGATE
                  (CONJUGATE OR CONJUGATES)
L5           88 L4 AND CONJUGATE

=> s l5 and (linker or "linking group" or linkage)
          29390 LINKER
           7330 LINKERS
          33734 LINKER
                  (LINKER OR LINKERS)
          56657 "LINKING"
            543 "LINKINGS"
          57079 "LINKING"
                  ("LINKING" OR "LINKINGS")
        1927147 "GROUP"
        1274857 "GROUPS"
        2683838 "GROUP"
                  ("GROUP" OR "GROUPS")
           4264 "LINKING GROUP"
                  ("LINKING"(W)"GROUP")
         100541 LINKAGE
          31507 LINKAGES
         126576 LINKAGE
                  (LINKAGE OR LINKAGES)
L6             8 L5 AND (LINKER OR "LINKING GROUP" OR LINKAGE)

=> d l6 1-8 abs ibib hitstr

L6   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
AB   The invention provides major histocompatibility complex (MHC) multimers
     comprising: (a) one or more MHC class I or class II antigens; (b) one or
     more antigenic peptides from pathogenic organisms (such as Borrelia)
     capable of binding to the MHC antigens; (c) linker mols.; and
     (d) multimerization domains that bind to the MHC complex and
     linker, and synthetic and recombinant methods for producing said
```

MHC multimers. The invention relates that said MHC multimers contain labels that include dyes, enzymes and/or radioactive mols., and that the multimers may contain an addnl. mol. related to a biol. activity, such as T cell activation, antigen presentation and/or therapy. The invention also relates that the multimerization domains are different types of carrier or scaffold mols., and include small mols., polymers, streptavidin, IgG, cells, liposomes and/or beads. The invention also provides the amino acid sequences of antigen peptides from Borrelia proteins, such as flagellins, outer membrane proteins and heat-shock proteins. The invention further provides for the use of said MHC multimers in immunization of individuals against diseases, such as Lyme disease, birrekusis and recurring fever, and in the diagnosis of a disease, and/or in the detection of T cells specific for a particular antigen. Finally, the invention provides for various methods used in detecting T cells specific for particular antigens.

ACCESSION NUMBER: 2009:1082060 CAPLUS
DOCUMENT NUMBER: 151:334871
TITLE: Major histocompatibility complex (MHC) multimers specific for antigenic peptides from pathogens (such as Borrelia), their compositions, production and use in immunization, diagnosis and in detection of specific T cells
INVENTOR(S): Brix, Liselotte; Pedersen, Henrik; Scholler, Jorgen
PATENT ASSIGNEE(S): Dako Denmark A/S, Den.
SOURCE: PCT Int. Appl., 2053pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009106073	A2	20090903	WO 2008-DK451	20081230
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:		
DK 2008-295	A	20080228
US 2008-67831P	P	20080228
DK 2008-1011	A	20080717
US 2008-83481P	P	20080724
DK 2008-1380	A	20081001
US 2008-101931P	P	20081001

IT 59-05-2, Methotrexate
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MHC multimers specific for antigenic peptides from pathogens (such as Borrelia), their compns., production and use in immunization, diagnosis and in detection of specific T cells)

RN 59-05-2 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AB The present invention describes novel methods to generate MHC or HLA multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in anal. of T-cells in samples 5 including diagnostic and prognostic methods. Furthermore the use of MHC multimers in therapy are described, e.g. anti-tumor and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable target cells or isolation of specific T-cells capable of regulation of other immune cells.

ACCESSION NUMBER: 2009:24490 CAPLUS
DOCUMENT NUMBER: 150:142453
TITLE: MHC multimers and conjugates for use in diagnosis, prognosis and therapy of cancer, infection, immune and autoimmune disease
INVENTOR(S): Brix, Liselotte; Pedersen, Henrik; Jakobsen, Tina; Schoeller, Joergen; Lohse, Jesper; Brunstedt, Katja; Jacobsen, Kivin
PATENT ASSIGNEE(S): Dako Denmark A/S, Den.
SOURCE: PCT Int. Appl., 470pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009003492	A1	20090108	WO 2008-DK50167	20080703
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

DK 2007-972	A	20070703
DK 2007-973	A	20070703
DK 2007-974	A	20070703
DK 2007-975	A	20070703
US 2007-929581P	P	20070703

	US 2007-929582P	P	20070703
	US 2007-929583P	P	20070703
	US 2007-929586P	P	20070703

IT 59-05-2, Methotrexate
RL: ARU (Analytical role, unclassified); DGN (Diagnostic use); MOA (Modifier or additive use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MHC multimers and conjugates for use in diagnosis, prognosis and therapy of cancer, infection, immune and autoimmune disease)
RN 59-05-2 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AB There is provided an organic-inorg. composite material containing a single nanoparticle therein, which is prepared by individually dispersing hydrophilic inorg. nanoparticles having a uniform particle size and conjugating biodegradable polymers to the surface of the nanoparticle, and a method of preparing the same. More particularly, the preparation method of the present invention comprises the following steps: (1) preparing hydrophilic nanoparticles by conjugating organic substances having a thiol group and a hydrophilic amine group to the surface of a core or a core/shell inorg. nanoparticle protected with a surfactant through a metal-thiolate (M-S) bond between them; (2) adjusting the concentration of the hydrophilic nanoparticles prepared in step (1) to 2+10-6 M or less and treating them in a sonication bath to prepare individually dispersed nanoparticles in the form of a single particle; and (3) conjugating biopolymers to the nanoparticle individually dispersed in step (2) through the formation of an amide bond between them under treatment in a sonication bath. The organic-inorg. composite material of the present invention exhibits high efficient photoluminescence and photostability as well as excellent chemical stability, dispersibility in water, biocompatibility and targetibility. Thus, it can be effectively used as a raw material for bioimaging or film coating. In an example, a hydrophobic CdSe/CdS quantum-dot solution was mixed with HSCH2CH2NH2·HCl to give a precipitate which is then conjugated with polyethylene glycol monomethyl ether mono(succinimidyl succinate) to prepare a composite.
ACCESSION NUMBER: 2008:224261 CAPLUS
DOCUMENT NUMBER: 148:239986
TITLE: Single nanoparticle containing organic-inorganic composite material and method of preparing the same
INVENTOR(S): Woo, Kyoungja; Koo, Dong Hyun
PATENT ASSIGNEE(S): Korea Institute of Science & Technology, S. Korea
SOURCE: U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080044657	A1	20080221	US 2006-642772	20061219
US 7601391	B2	20091013		
KR 2008017149	A	20080226	KR 2006-78757	20060821
KR 809366	B1	20080305		

PRIORITY APPLN. INFO.: KR 2006-78757 A 20060821
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 148:239986
IT 59-05-2, Methotrexate
RL: RGT (Reagent); RACT (Reactant or reagent)
(targeting agent; manufacture of single nanoparticle-containing organic-inorg.
composite materials using hydrophilic linkers and conjugation)
RN 59-05-2 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
ACCESSION NUMBER: 2007:33392 CAPLUS
DOCUMENT NUMBER: 146:141003
TITLE: Human interleukin 12 subunit p40-binding antibodies, fragments and conjugates in combination with other therapeutic agents for treating IL-12-associated acute and chronic inflammatory disease
INVENTOR(S): Lacy, Susan E.; Fung, Emma; Belk, Jonathan P.; Dixon, Richard W.; Roguska, Michael; Hinton, Paul R.; Kumar, Shankar

PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 211pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007005608	A2	20070111	WO 2006-US25584	20060629
WO 2007005608	A3	20081009		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006265932	A1	20070111	AU 2006-265932	20060629
CA 2612239	A1	20070111	CA 2006-2612239	20060629
EP 1907421	A2	20080409	EP 2006-785967	20060629
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009500018	T	20090108	JP 2008-519612	20060629
BR 200611714	A2	20090113	BR 2006-11714	20060629
IN 2007DN09729	A	20080620	IN 2007-DN9729	20071214
MX 2007016401	A	20080220	MX 2007-16401	20071218
KR 2008028895	A	20080402	KR 2007-730917	20071228
CN 101379085	A	20090304	CN 2006-80024097	20071229
NO 2008000557	A	20080130	NO 2008-557	20080130

PRIORITY APPLN. INFO.:
US 2005-695679P P 20050630
WO 2006-US25584 W 20060629

IT 59-05-2, Methotrexate
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human interleukin 12 subunit p40-binding antibodies, fragments and conjugates in combination with other therapeutic agents for treating IL-12-associated acute and chronic inflammatory disease)

RN 59-05-2 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AB Disclosed is a hyaluronic acid/methotrexate compound useful as a therapeutic agent for joint diseases. The hyaluronic acid/methotrexate compound useful for the treatment of joint diseases comprises hyaluronic acid and methotrexate bonded to a hydroxy group of the acid through a linker having a peptide chain comprising one to eight amino acids, the linker being bonded to the hyaluronic acid through a carbamate group. Thus, a methotrexate derivative [MTX(Et)-α-PhePhe-NH-C10H20O3-NH2] was prepared and reacted with p-nitrophenylchloroformate. The obtained phenylcarbamate compound 4,7,10-trioxa-13-[N-[N-[N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-α-(O5-methylglutamyl)]phenylalanyl]phenylalanylamino]tridecanylamine [MTX(Et)-α-PhePhe-NH-C10H20O3-NHCO-O-C6H4-NO2] was reacted with sodium hyaluronate to give a hyaluronic acid /methotrexate compound of the present invention. The compound showed excellent antiarthritic effect in rat.

ACCESSION NUMBER: 2005:1103818 CAPLUS
DOCUMENT NUMBER: 143:392980
TITLE: Hyaluronic acid/methotrexate compound
INVENTOR(S): Ikeya, Hitoshi; Morikawa, Tadashi; Takahashi, Koichi; Izutani, Noriyuki; Tamura, Tatsuya; Okamachi, Akira; Ishizawa, Takenori; Sato, Haruhiko; Higuchi, Yoshinobu; Kato, Tatsuya; Honma, Akie
PATENT ASSIGNEE(S): Denki Kagaku Kogyo Kabushiki Kaisha, Japan; Chugai Seiyaku Kabushiki Kaisha
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095464	A1	20051013	WO 2005-JP6472	20050401
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1739097	A1	20070103	EP 2005-727780	20050401
R: DE, ES, FR, GB, IT				
US 20090093414	A1	20090409	US 2008-547158	20080529

PRIORITY APPLN. INFO.: JP 2004-110423 A 20040402
JP 2004-110243 A 20040402
WO 2005-JP6472 W 20050401

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:392980
IT 59-05-2DP, Methotrexate, reaction products with linker peptides and hyaluronate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hyaluronic acid/methotrexate compds. including peptide linkers for treatment of joint disease)

RN 59-05-2 CAPLUS

CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AB Disclosed is a hyaluronic acid/methotrexate compound useful as a therapeutic agent for joint diseases. The hyaluronic acid/methotrexate compound useful as a therapeutic agent for joint diseases comprises hyaluronic acid and methotrexate bonded to a carboxy group of the acid through a linker having a peptide chain comprising one to eight amino acids. For example, 2-[N-[N-[N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-α-(O5-methylglutamyl)]phenylalanyl]phenylalanylamino]ethylamine (MTX-α-PhePhe-NHC2H4NH2) was prepared and reacted with sodium hyaluronate to obtain a conjugate, to examine its effect in arthritis model rats.

ACCESSION NUMBER: 2005:1004784 CAPLUS

DOCUMENT NUMBER: 143:292584

TITLE: Hyaluronic acid/methotrexate compound

INVENTOR(S): Ikeya, Hitoshi; Morikawa, Tadashi; Takahashi, Koichi; Tamura, Tatsuya; Okamachi, Akira; Ishizawa, Takenori; Sato, Haruhiko; Higuchi, Yoshinobu

PATENT ASSIGNEE(S): Denki Kagaku Kogyo Kabushiki Kaisha, Japan; Chugai Seiyaku Kabushiki Kaisha

SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085294	A1	20050915	WO 2005-JP3739	20050304

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005219733	A1	20050915	AU 2005-219733	20050304
CA 2559188	A1	20050915	CA 2005-2559188	20050304
EP 1724287	A1	20061122	EP 2005-720011	20050304
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1946743	A	20070411	CN 2005-80012963	20050304
US 20070197465	A1	20070823	US 2006-591653	20060905
KR 2007006798	A	20070111	KR 2006-719810	20060925
IN 2006CN03685	A	20070706	IN 2006-CN3685	20061005
PRIORITY APPLN. INFO.:			JP 2004-62616 A	20040305
			JP 2004-167755 A	20040604
			WO 2005-JP3739 W	20050304

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:292584
IT 59-05-2D, Methotrexate, conjugates with hyaluronic acids with peptide linkers
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hyaluronic acid/methotrexate compds. with peptide linkers for treatment of joint disease, and preparation thereof)
RN 59-05-2 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention relates to methods for. the production of monomeric cytotoxic drug/carrier conjugates (the "conjugates") with higher drug loading and substantially reduced low conjugate fraction (LCF). Cytotoxic drug derivative/antibody conjugates, compns. comprising the conjugates and uses of the conjugates are also described. Particularly, the invention relates to anti-CD22 antibody-monomeric calicheamicin conjugates . The invention also relates to the conjugates of the invention, to methods of purification of the conjugates, to pharmaceutical compns. comprising the conjugates, and to uses of the conjugates.
ACCESSION NUMBER: 2003:892567 CAPLUS

DOCUMENT NUMBER: 139:386334
TITLE: Production of monomeric calicheamicin derivative cytotoxic drug/carrier conjugates
INVENTOR(S): Kunz, Arthur; Moran, Justin Keith; Rubino, Joseph Thomas; Jain, Neera; Vidunas, Eugene Joseph; Simpson, John McLean; Robbins, Paul David; Merchant, Nishith; Dijoseph, John Francis; Ruppen, Mark Edward; Damle, Nitin Krishnaji; Popplewell, Andrew George; et al.
PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092623	A2	20031113	WO 2003-US13910	20030502
WO 2003092623	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483552	A1	20031113	CA 2003-2483552	20030502
AU 2003231293	A1	20031117	AU 2003-231293	20030502
EP 1507556	A2	20050223	EP 2003-724432	20030502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005524700	T	20050818	JP 2004-500808	20030502
CN 1665532	A	20050907	CN 2003-815260	20030502
CN 100482277	C	20090429		
BR 2003009868	A	20051018	BR 2003-9868	20030502
NO 2004004663	A	20050125	NO 2004-4663	20041028
MX 2004010792	A	20050307	MX 2004-10792	20041029
IN 2004KN01802	A	20060106	IN 2004-KN1802	20041129
IN 2007KN01141	A	20080801	IN 2007-KN1141	20070402
AU 2009202609	A1	20090716	AU 2009-202609	20090626

PRIORITY APPLN. INFO.:	US 2002-377440P	P	20020502
	AU 2003-231293	A3	20030502
	WO 2003-US13910	W	20030502
	IN 2004-KN1802	A3	20041129

IT 59-05-2, Methotrexate
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (production of monomeric calicheamicin derivative cytotoxic drug/carrier conjugates)
RN 59-05-2 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

AB The present invention provides protein conjugates having a glucose-aminoglycan-targeting domain conjugated directly or indirectly to a therapeutically useful protein via chemical or peptidyl linkage. A conjugate of the invention is disclosed in which a hyaluronan-binding protein is a receptor for hyaluronic acid-mediated mobility (RHAMM). The protein conjugates selectively target certain tissues and organs and are useful for treating or preventing various physiol. and pathol. conditions. Methods of their use and preparation are described.

ACCESSION NUMBER: 2001:798086 CAPLUS
DOCUMENT NUMBER: 135:348866
TITLE: RHAMM peptide conjugates for drug targeting
INVENTOR(S): Woloski, B. Michael R.; Williams, Ashley Martin; Sereda, Terrance Jimmy; Wiebe, Deanna June
PATENT ASSIGNEE(S): Cangene Corporation, Can.
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080899	A2	20011101	WO 2001-CA533	20010420
WO 2001080899	A3	20020906		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2406593	A1	20011101	CA 2001-2406593	20010420
EP 1274461	A2	20030115	EP 2001-923439	20010420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040037834	A1	20040226	US 2003-257377	20030610
PRIORITY APPLN. INFO.:			US 2000-198613P P	20000420
			WO 2001-CA533 W	20010420

OTHER SOURCE(S): MARPAT 135:348866

IT 59-05-2DP, Methotrexate, RHAMM conjugates
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(RHAMM peptide conjugates for drug targeting)
RN 59-05-2 CAPLUS
CN L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 16:42:34 ON 13 DEC 2009